KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Ionis Pharmaceuticals (IONS) over the last 16 years, with Q3 2025 value amounting to $213000.0.

  • Ionis Pharmaceuticals' Tax Provisions rose 10588.24% to $213000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.4 million, marking a year-over-year decrease of 17772.29%. This contributed to the annual value of -$6.2 million for FY2024, which is 11909.28% down from last year.
  • Latest data reveals that Ionis Pharmaceuticals reported Tax Provisions of $213000.0 as of Q3 2025, which was up 10588.24% from -$20000.0 recorded in Q2 2025.
  • In the past 5 years, Ionis Pharmaceuticals' Tax Provisions ranged from a high of $11.4 million in Q1 2023 and a low of -$3.6 million during Q3 2024
  • In the last 5 years, Ionis Pharmaceuticals' Tax Provisions had a median value of $300000.0 in 2022 and averaged $2.0 million.
  • Its Tax Provisions has fluctuated over the past 5 years, first skyrocketed by 222091.69% in 2022, then tumbled by 15484.7% in 2024.
  • Ionis Pharmaceuticals' Tax Provisions (Quarter) stood at $349000.0 in 2021, then surged by 2220.92% to $8.1 million in 2022, then dropped by 19.8% to $6.5 million in 2023, then tumbled by 141.12% to -$2.7 million in 2024, then soared by 107.97% to $213000.0 in 2025.
  • Its Tax Provisions was $213000.0 in Q3 2025, compared to -$20000.0 in Q2 2025 and $116000.0 in Q1 2025.